HEALTH PROFESSIONAL · SOURCE READING

Targeted therapy

Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer / Treatment Options for Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer

Patients with targetable pathogenic variants can consider clinical trials of investigational therapies. Currently, targeted therapies have only been approved for patients whose disease has progressed or who are ineligible for first-line therapies.

Continue within this section

IDH1 inhibitors →FGFR inhibitors →HER2-targeted therapy →

Preserved source evidence · Not medical advice